Abstract Library

#4637 Non-functional retroperitoneal paraganglioma in a young patient: A case report

Introduction: Paragangliomas are neuroendocrine tumours arising in the parasympathetic nervous system, outside the adrenal gland. Retroperitoneal location is extremely rare. Non-functional paragangliomas often represent a diagnostic challenge.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: retroperitoneal paraganglioma, surgery, monitoring,

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4569 Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,

#4543 Single-cell transcriptomic landscape indicates the potential role of immunotherapy in metastatic pancreatic angiosarcoma

Introduction: Pancreatic angiosarcoma is a rare and highly aggressive tumour originated from lymphatic or vascular endothelial cells, with poor prognosis and few effective treatments. However, little is known about its tumour microenvironment and the mechanisms of its progression.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Lin X, Peng S,

Keywords: pancreatic angiosarcoma, single-cell RNA sequencing, immunotherapy, PD-L1, CD86,

#4519 ANXA1-labelled cancer-associated fibroblasts induces tumour invasion and immunosuppressive microenvironment

Introduction: The growth pattern of a tumour is a marker for distinguishing inert from invasive tumours. In general, tumours such as the encapsulated follicular variant of papillary thyroid carcinoma show expansive growth. In contrast, invasive tumours, such as colorectal cancer and squamous cell carcinoma of the tongue, show invasive growth with infiltration into surrounding structures and have a poorer prognosis. Pancreatic neuroendocrine neoplasm (PNEN) is the heterogeneous tumour originating from peptidergic neurons and neuroendocrine cells. PNEN with a high proportion of tumour mesenchyme, especially those presenting an infiltrating stroma, have a poor prognosis. In the infiltrating mesenchyme, cancer-associated fibroblasts (CAF) play an important role. However, little research has been done on the mechanisms of how infiltrating CAF affects tumour malignancy and immune microenvironment.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Xu J, Chen J, Xu X, Ji S,

Keywords: pancreatic neuroendocrine neoplasm, tumour-associated fibroblasts, immunosuppressive microenvironment,